Evergreen Theragnostics, a clinical stage contract development and manufacturing organization (CDMO) developing innovative radiopharmaceuticals for cancer therapy, has successfully completed a $15M Series B capital raise. With existing shareholders exercising their rights of first refusal, this major investment will allow Evergreen Theragnostics to further expand its groundbreaking efforts in providing groundbreaking treatments to fight cancer.
Evergreen is excited to launch its new business unit, Evergreen Discovery, dedicated to developing groundbreaking radiopharmaceuticals for cancer therapy. To support this endeavor, the company has brought on board Dr. Thomas Reiner, a highly experienced expert in radioligand therapy drug discovery. He was formerly a member of the Executive Leadership Team of AAA (Advanced Accelerator Applications, a Novartis Company) and a Laboratory Head and Associate Professor at Memorial Sloan Kettering Cancer Center. With Dr. Reiner’s leadership, Evergreen is confident that the new business unit will be a success.
I am thrilled to join the team at Evergreen Theragnostics and take the helm of their new R&D business unit, Evergreen Discovery. With a strong reputation in the radiopharmaceutical field, it was an easy decision to join the Evergreen family. Radioligand Therapy is a revolutionary treatment for some of the most aggressive types of cancer, and I am eager to lead the charge in innovating this therapeutic modality. Our team will focus on developing groundbreaking and pioneering radiopharmaceuticals to revolutionize how we treat cancer.
Evergreen Theragnostics is thrilled to announce the launch of Evergreen Discovery, and the recruitment of Thomas as its leader. This is an exciting step forward for the company, and a chance to develop innovative radiopharmaceuticals to combat some of the most critical unmet clinical needs. As President and CEO, James Cook expresses his enthusiasm for the new venture, emphasizing the importance of the team’s mission.
In Q3’2023, a state-of-the-art research facility will be unveiled near Princeton, NJ, marking the beginning of a new era for Evergreen Discovery. The facility promises to provide unprecedented opportunities for scientific exploration and discovery, setting the stage for a bright future.
Evergreen is gearing up to launch Ga-68 DOTATOC if approved, utilizing funds raised from its recent capital raise. To ensure success, Evergreen is investing in building commercial capabilities, staffing, and inventory build. With the launch, Evergreen’s radiopharmacy partners across the country will have access to the product. With the preparation underway, Evergreen is ready to bring this innovative product to the public.
At Evergreen, we are dedicated to providing cancer patients with better options through radiopharmaceuticals. This funding will enable us to continue striving towards this goal, including through our core CDMO business, the development of Ga-68 DOTATOC, and the launch of Evergreen Discovery. We are thrilled to have secured this important funding, and we look forward to making an impact on the lives of those affected by cancer.
About Evergreen Theragnostics, Inc.
Evergreen Theragnostics is revolutionizing cancer treatment with radiopharmaceuticals. Established in 2019, this cutting-edge company, based in Springfield, NJ, has a state-of-the-art GMP radiopharmaceutical facility and is committed to three core areas: CDMO, Products, and Drug Discovery. Led by an experienced team with a proven track record in theragnostic radiopharmaceutical manufacturing and commercialization, Evergreen Theragnostics is poised to make a real impact in cancer care.